Personalized Management of Miscellaneous Disorders



Similar to the concept of personalized medicine based on patients’ genetic differences, treatment of infectious diseases involves individualizing therapy according to genetic differences in infectious agents. The main example is that of HIV infection. There are two variable factors in HIV/AIDS – how people respond to the HIV and how HIV responds to drugs. Research in vaccinology is playing an important role in relation to immunology of HIV/AIDS.


Rheumatoid Arthritis Inflammatory Bowel Disease Natural Killer Cell Angiotensin Converting Enzyme Sustained Virologic Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Andrade A, Flexner C (2004) Genes, ethnicity, and efavirenz response: clinical pharmacology update from the 11th CROI. Hopkins HIV Rep 16:1–7PubMedGoogle Scholar
  2. Aurora R, Donlin M, Cannon NA et al (2009) Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest 119:225–236PubMedGoogle Scholar
  3. Camilleri M (2007) Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications. Neurogastroenterol Motil 19(s2):40–45CrossRefPubMedGoogle Scholar
  4. Chaussabel D, Allman W, Mejias A et al (2005) Analysis of significance patterns identifies ubiquitous and disease-specific gene-expression signatures in patient peripheral blood leukocytes. Ann N Y Acad Sci 1062:146–154CrossRefPubMedGoogle Scholar
  5. Cobb JP, Mindrinos MN, Miller-Graziano C et al (2005) Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci USA 102:4801–4806CrossRefPubMedGoogle Scholar
  6. Dionne RA, Bartoshuk L, Mogil J, Witter J (2005) Individual responder analyses for pain: does one pain scale fit all? Trends Pharmacol Sci 26:125–130CrossRefPubMedGoogle Scholar
  7. Fu Liang NG, Holt DW, MacPhee I (2007) Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opin Pharmacother 8:2045–2058CrossRefGoogle Scholar
  8. Ingelman-Sundberg M (2008) Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 358:637–639CrossRefPubMedGoogle Scholar
  9. Israel E, Chinchilli VM, Ford JG et al (2004) Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364:1505–1512CrossRefPubMedGoogle Scholar
  10. Jain KK (2009l) Textbook of hyperbaric medicine, 5th edn, Hogrefe & Huber, Göttingen.CrossRefGoogle Scholar
  11. Kim S, Poursine-Laurent J, Truscott SM et al (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436:709–713CrossRefPubMedGoogle Scholar
  12. Lugogo NL, Ginsburg GS, Que LG (2007) Genetic profiling and tailored therapy in asthma: are we there yet? Curr Opin Mol Ther 9:528–537PubMedGoogle Scholar
  13. Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney International 67:1704–1709 Google Scholar
  14. Plenge RM, Seielstad M, Padyukov L et al (2007) TRAF1-C5 as a risk locus for rheumatoid arthritis – a genomewide study. N Engl J Med 357:1199–1209CrossRefPubMedGoogle Scholar
  15. Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285–2293CrossRefPubMedGoogle Scholar
  16. Rodriguez-Torres M, Jeffers LJ, Sheikh MY et al (2009) Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 360:257–267CrossRefPubMedGoogle Scholar
  17. Ross JR, Rutter D, Welsh K et al (2005) Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 5:324–336CrossRefPubMedGoogle Scholar
  18. Rudnicki M, Mayer G (2003) Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease – pathophysiological considerations. Pharmacogenomics 4:153–162CrossRefPubMedGoogle Scholar
  19. Rutter JL (2006) Symbiotic relationship of pharmacogenetics and drugs of abuse. AAPS J 8:E174–E184CrossRefPubMedGoogle Scholar
  20. Takei Y, Sawada T, Sameshima S, Nagasako K (2001) Post-genome challenges against inflammatory bowel diseases. Nippon Rinsho 59:180–184Google Scholar
  21. Taniguchi A, Urano W, Tanaka E, Kamatani N (2007) Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis. Nippon Rinsho 65:371–379PubMedGoogle Scholar
  22. Tozzi V, Libertone R, Liuzzi G (2008) HIV pharmacogenetics in clinical practice: recent achievements and future challenges. Curr HIV Res 6:544–554CrossRefPubMedGoogle Scholar
  23. Werely CJ, Donald PR, van Helden PD (2007) NAT2 polymorphisms and their influence on the pharmacology and toxicity of isoniazid in TB patients. Personal Med 4:123–131CrossRefGoogle Scholar
  24. Williams DG, Patel A, Howard RF (2002) Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth 89:839–845CrossRefPubMedGoogle Scholar
  25. Woolf CJ; American College of Physicians; American Physiological Society (2004) Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 140:441–451PubMedGoogle Scholar
  26. Yudkin P, Munafo M, Hey K et al (2004) Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328:989–990CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations